target patient

tar·get pa·tient

in group therapy, the patient being analyzed in turn by another member patient.

target patient

A term of art for a patient in the UK who is in a queue to receive a particular health service within a specified (“target”) timeframe—e.g., being seen by an oncologist within 31 days of an urgent GP referral.
References in periodicals archive ?
Gluskin stated "The versatility of the sub-micron platform technology will continue to validate the company's sub-micron approach and provide a unique opportunity to offer different absorption-enhanced products to widen the target patient population.
Orphan drug designation by the FDA is granted upon recognition that the prevalence of the US target patient population is 200,000 or less.
Having rapid and accurate microbial identification to improve and target patient therapy made clear the potential for microbial identification where the microbes can be placed directly onto the target slide without purification steps.
Professor Tony Bjourson, director of the UU Biomedical Sciences Research Institute said: "The objective of this personalised medicine fellowship and indeed stratified medicine in general is to better target patient drug treatment and care based on personal genetic information about a patient.
Thoelke will discuss how the key to successful recruitment is using the right data and algorithms to locate the target patient population.
More broadly, the results improve understanding of the underlying mechanisms responsible for hypnotic phenomena and suggest that future hypnotic interventions target patient expectancies and distress to improve postsurgical recovery.
Correlating the mechanisms of drug action with disease and patient characteristics facilitates selection of appropriate clinical trial endpoints and defines target patient populations most likely to obtain medical benefit.
THE EUROPEAN Commission has published guidance over staging consultations with target patient groups for checking the readability of packaging leaflets-http://pharmacos.
The resultant DME genetic profile provides invaluable data to assist with interpretation of trial results and potentially on the criteria for target patient groups after the drug is launched.
The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
has now completed target patient enrollment in two, pivotal Phase III clinical trials of the Toll-like receptor 9 (TLR9) agonist drug candidate, PF-3512676, for the treatment of advanced non-small cell lung cancer (NSCLC).
Coram says the group will focus on helping companies engaged in Phase II-IV studies and expedite their clinical trials by gaining rapid access to target patient populations.